Center for Ophthalmology, Eberhard Karls University Tuebingen, Tuebingen, Germany.
JAMA Ophthalmol. 2013 May;131(5):630-7. doi: 10.1001/jamaophthalmol.2013.697.
The present study intended to analyze the suitability of single-dose stereotactic radiotherapy in the treatment of uveal melanoma that cannot be handled with ruthenium-brachytherapy and therefore is a challenge for ophthalmologists concerning local tumor control, as well as preservation of the eye and visual function.
To evaluate local tumor control, eye preservation, visual course, radiation complications, metastases, and death after single-dose stereotactic radiotherapy (SDRT) applied exclusively or combined with tumor resection in uveal melanomas that are neither suitable nor favorably located for ruthenium brachytherapy.
Retrospective, observational case series.
Primary care center.
Seventy-eight patients with uveal melanoma were treated.
Between June 3, 2003, and March 18, 2008, patients with uveal melanoma received SDRT monotherapy (group 1, 60 patients) or SDRT combined with tumor resection (group 2, 18 patients). Radiotherapy was performed with a tumor-surrounding dose of 25 Gy on a linear accelerator.
Local tumor control, eye preservation, visual results, and radiation complications.
Within a median follow-up of 33.7 months (range, 0.13-81.13 months), 6 recurrences occurred in group 1; none recurred in group 2. The Kaplan-Meier estimate for local control was 85% at 3 years in group 1 and 100% in group 2 (P = .22). Eye preservation rate was 77% vs 87% at 3 years (groups 1 and 2, respectively) (P = .82). Visual acuity decreased with a median loss of -18 Snellen lines (group 1) and -22 Snellen lines (group 2). More retinopathies (P = .07), opticopathies (P = .27), and rubeotic glaucomas (P = .10) occurred in group 1. No significant difference was observed in the development of metastases (P = .33). The groups differed in overall survival because of 2 deaths occurring shortly after surgery in group 2 for unexplained reasons (P = .06).
Survival analysis suggested that SDRT with combined tumor resection might be associated with increased tumor control and fewer radiation complications than SDRT as monotherapy. Both groups had similar eye retention rates and were comparable concerning the decrease in visual function in most eyes. However, the protocol was stopped after 3 unexplainable deaths after surgery.
本研究旨在分析单次立体定向放射治疗(SDRT)在治疗无法采用钌近距离放射疗法治疗的葡萄膜黑色素瘤中的适用性,因为对于眼科医生而言,局部肿瘤控制以及保留眼球和视力功能是一个挑战。
评估 SDRT 单独或联合肿瘤切除术治疗不适合或位置不佳的钌近距离放射疗法的葡萄膜黑色素瘤的局部肿瘤控制、眼球保留、视力变化、放射并发症、转移和死亡情况。
回顾性、观察性病例系列。
基层医疗中心。
78 例葡萄膜黑色素瘤患者接受治疗。
2003 年 6 月 3 日至 2008 年 3 月 18 日,葡萄膜黑色素瘤患者接受 SDRT 单药治疗(第 1 组,60 例)或 SDRT 联合肿瘤切除术(第 2 组,18 例)。放疗在直线加速器上使用肿瘤周围剂量 25 Gy 进行。
局部肿瘤控制、眼球保留、视力结果和放射并发症。
中位随访 33.7 个月(范围,0.13-81.13 个月)后,第 1 组中有 6 例复发,第 2 组中无复发。第 1 组和第 2 组的局部控制的 Kaplan-Meier 估计值分别为 3 年时的 85%和 100%(P =.22)。第 1 组和第 2 组的眼球保留率分别为 3 年时的 77%和 87%(P =.82)。视力下降中位数为-18 行 Snellen 视力表(第 1 组)和-22 行 Snellen 视力表(第 2 组)。第 1 组的视网膜病变(P =.07)、视神经病变(P =.27)和新生血管性青光眼(P =.10)更多。转移的发生无显著差异(P =.33)。由于第 2 组有 2 例患者在手术后不久因不明原因死亡(P =.06),两组的总生存率不同。
生存分析表明,与 SDRT 单药治疗相比,SDRT 联合肿瘤切除术可能与更高的肿瘤控制率和更少的放射并发症相关。两组的眼球保留率相似,并且大多数眼睛的视力下降情况相似。然而,由于手术后出现 3 例不明原因死亡,该方案被停止。